Synergistic anticancer activity of curcumin and catechin: An in vitro study using human cancer cell lines

2011 ◽  
Vol 75 (2) ◽  
pp. 112-116 ◽  
Author(s):  
R. Manikandan ◽  
M. Beulaja ◽  
C. Arulvasu ◽  
S. Sellamuthu ◽  
D. Dinesh ◽  
...  
2013 ◽  
Vol 35 (8) ◽  
pp. e51-e52 ◽  
Author(s):  
F. Foglietta ◽  
R. Canaparo ◽  
A. Francovich ◽  
P. Civera ◽  
L. Serpe

BMB Reports ◽  
2005 ◽  
Vol 38 (5) ◽  
pp. 526-532 ◽  
Author(s):  
Vikram Dhuna ◽  
Jagmohan Singh Bains ◽  
Sukhdev Singh Kamboj ◽  
Jatinder Singh ◽  
Shanmugavel ◽  
...  

2018 ◽  
Vol 23 (2) ◽  
pp. 68
Author(s):  
Eti Nurwening Sholikhah ◽  
Jumina Jumina ◽  
Sitarina Widyarini ◽  
Ruslin Hadanu ◽  
Mustofa Mustofa

This research was conducted to evaluate the anticancer activity of new compounds of benzyl-1,10- phenanthroline derivatives and their selectivity. In vitro anticancer activity of 11 benzyl-1,10-phenanthroline derivatives were conducted on three human cancer cell lines, cervical cancer (HeLa), myeloma (NS-1), and breast cancer (MCF-7) using MTT-based cytotoxicity assay. The cytotoxicity of each compound was assessed to normal Vero cell line by the same method. The in vitro anticancer activity and cytotoxicity was expressed by the concentration inhibiting 50% of the cell growth (IC50), and the selectivity index (SI) was determined by calculating ratio of the IC50 on Vero cell line and the human cancer cell lines. The results showed that among the 11 compounds tested, the (1)-N-(4-butoxybenzyl)-1,10-phenanthrolinium bromide exhibited the best in vitro anticancer activity with an IC50 27.60 ± 2.76 µM on HeLa, 6.42 ± 5.53 µM on NS-1 and 9.44 ± 2.17 µM on MCF-7 cell lines. Its SI were 377.65 ± 39.97 on HeLa, 6158.72 ± 5306.34 on NS-1 and 1140.11 ± 261.85 on MCF-7 cell lines. This study demonstrated that (1)-N-(4-butoxybenzyl)-1,10-phenanthrolinium bromide possessed a potential in vitro anticancer activity on cancer cell lines with high selectivity


2020 ◽  
Vol 17 (5) ◽  
pp. 345-351
Author(s):  
Syndla Premalatha ◽  
G. Rambabu ◽  
Islavathu Hatti ◽  
Dittakavi Ramachandran

A new series of 3-(3,4,5-trimethoxyphenyl)-5-(2-(5-arylbenzo[b]thiophen-3-yl)oxa zol-5- yl)isoxazole derivatives were designed and synthesized. All these derivatives were evaluated for their anticancer activity against various human cancer cell lines such as MCF-7 (breast cancer), A549 (lung cancer), DU-145 (prostate cancer) and MDA MB-231 (breast cancer)-four human cancer cell lines by using MTT assay. Here, etoposide was used as a standard reference drug and most of the compounds were exhibited good anticancer activity with respect to cell lines. Among all compounds, five compounds 11b, 11c, 11f, 11i and 11j showed more potent activity than standard drug, in which, compound 11f was the most promising compound.


Sign in / Sign up

Export Citation Format

Share Document